Mathys & Squire will be offering a webinar entitled "Plausibility at the EPO - Exploring the Legacy of Dasatinib" on September 22, 2020 from 6:00 to 7:00 pm (GMT Summer Time); 11:00 am to 12:00 pm (ET). Anna Gregson and Stpehne Garner of Mathys & Squire LLP will review how the EPO case law has developed since the EPO Board of Appeal revoked Bristol-Myers Squib's dasatinib patent in 2017, and discuss if and how innovators should adjust their filing and drafting strategy in light of the EPO's post-dasatinib approach to plausibility.
While there is no cost to participate in the program, those interested in attending the webinar can register here.
Comments